Current radiopharmaceuticals最新文献

筛选
英文 中文
[68Ga]Ga-DOTA-TOC Synthesis by a Cassette Developer System with [68Ga]GaCl3 from Cyclotron using Liquid Target: An Italian Experience. [68Ga]GaCl3液体靶回旋加速器盒式显影系统合成[68Ga]Ga-DOTA-TOC的意大利经验
IF 1.5 4区 医学
Current radiopharmaceuticals Pub Date : 2025-05-09 DOI: 10.2174/0118744710379515250506045145
Michela Cossandi, Massimo Statuto, Giorgio Biasiotto, Gian Luca Viganò, Luca Camoni, Elena Migliorati, Carlo Rodella, Federica Saiani, Luigi Spiazzi, Francesco Bertagna
{"title":"[68Ga]Ga-DOTA-TOC Synthesis by a Cassette Developer System with [68Ga]GaCl3 from Cyclotron using Liquid Target: An Italian Experience.","authors":"Michela Cossandi, Massimo Statuto, Giorgio Biasiotto, Gian Luca Viganò, Luca Camoni, Elena Migliorati, Carlo Rodella, Federica Saiani, Luigi Spiazzi, Francesco Bertagna","doi":"10.2174/0118744710379515250506045145","DOIUrl":"https://doi.org/10.2174/0118744710379515250506045145","url":null,"abstract":"<p><strong>Background: </strong>[68Ga-DOTA-D-Phe1-Tyr3]octreotide ([68Ga]Ga-DOTA-TOC) is a somatostatin analogue largely used in PET/CT applications for the detection of gastroenteropancreatic neuroendocrine tumors (GEP-NET). Initially, it was obtained using a 68Ge/68Ga generator.</p><p><strong>Objective: </strong>The increasing cost of good manufacturing practice-compliant generators has led to the need to find alternative ways of producing Gallium-68 (68Ga). The goal of this work is to show the production optimization of [68Ga]Ga-DOTA-TOC via cyclotron, derived from three years of experience.</p><p><strong>Methods: </strong>The production of [68Ga]GaCl3 via the 68Zn(p,n)68Ga reaction was optimized using a PETtrace 800 cyclotron (equipped with ZnO liquid target) and synthesis of [68Ga]Ga-DOTATOC was performed by FASTlab2 developer system according to the Guidelines on Good Radiopharmacy Practice (cGRPP). Quality control process was validated according to the current specific monograph (2482) of the European Pharmacopoeia (Ph. Eur.) before clinical use.</p><p><strong>Results: </strong>[68Ga]Ga-DOTA-TOC was produced in 40 minutes; ten validation batches met the quality criteria expected by the Ph. Eur. The synthesis process has involved many issues due to the use of acidic reagents and related corrosion of some components of the cyclotron and developer system, resulting in 12.2% failed syntheses and a target breakdown after 11 months. In the troubleshooting section are reported the main issues, their causes and the strategies used to solve them. Thanks to these strategies, the number of failed syntheses has decreased and today, we have achieved a 0% failure rate.</p><p><strong>Conclusion: </strong>Liquid target production of [68Ga]Ga-DOTA-TOC, once consolidated, instead of 68Ge/68Ga generator has many advantages.</p>","PeriodicalId":10991,"journal":{"name":"Current radiopharmaceuticals","volume":" ","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143983133","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evaluating the Effectiveness of Geant4 Software in Measuring the Damage Caused by Ti48 Ion Radiation on Nerve Cells, in Comparison to the Biophysical Model and Empirical Data. 评价Geant4软件测量Ti48离子辐射对神经细胞损伤的有效性,比较生物物理模型和经验数据。
IF 1.5 4区 医学
Current radiopharmaceuticals Pub Date : 2025-05-08 DOI: 10.2174/0118744710367266250506050409
Habiballah Moradi, Eman Obeidavi, Akbar Aliasgharzadeh, Bagher Farhood, Mohammad Esmail Shahabodin
{"title":"Evaluating the Effectiveness of Geant4 Software in Measuring the Damage Caused by Ti48 Ion Radiation on Nerve Cells, in Comparison to the Biophysical Model and Empirical Data.","authors":"Habiballah Moradi, Eman Obeidavi, Akbar Aliasgharzadeh, Bagher Farhood, Mohammad Esmail Shahabodin","doi":"10.2174/0118744710367266250506050409","DOIUrl":"https://doi.org/10.2174/0118744710367266250506050409","url":null,"abstract":"<p><strong>Introduction: </strong>Presently, heavy particle ion radiation therapy is commonly utilized for the treatment of deep-seated malignancies, such as brain tumors. In addition to tumor treatment, these particles may negatively impact healthy nerve cells. Therefore, it is essential to investigate the radiobiological effects of these radiations on cells. Simulation studies that model the radiation of heavy particles and the exact geometrical configuration of nerve cells are essential and effective in evaluating potential cellular damage.</p><p><strong>Materials and methods: </strong>The NEURON software was employed in Geant4 code to simulate an individual nerve cell (ID no: NMO 06176) and a network of ten neural cells subjected to bombardment by Ti48 ion particles at an energy of 600 MeV/u.</p><p><strong>Results: </strong>The absorbed energy differs among several components of individual cells and neural networks, including the soma and dendrites. The absorbed doses from Ti48 radiation in individual nerve cells and dendritic networks surpass those in the cell body, and this ratio remains consistent as the dosage escalates. The decrease in the initial length of dendrites in both individual cells and neuronal networks intensifies with increased dosages.</p><p><strong>Conclusion: </strong>The diminution of dendritic length due to Ti48 radiation is more significant within the cellular network compared to isolated nerve cells.</p>","PeriodicalId":10991,"journal":{"name":"Current radiopharmaceuticals","volume":" ","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143994542","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Synergistic Potential of GLP-1 Receptor Agonists and Radiotherapy in Breast Cancer Treatment: A New Therapeutic Avenue (TROD-GROG 006). GLP-1受体激动剂和放疗在乳腺癌治疗中的协同潜力:一条新的治疗途径(TROD-GROG 006)。
IF 1.5 4区 医学
Current radiopharmaceuticals Pub Date : 2025-05-06 DOI: 10.2174/0118744710381356250429045716
Ozum Atasoy, Elvan Anadol, Atiye Seda Yar Sağlam, Eyüb Yaşar Akdemir, Yasemin Şengün Coşkun, Ece Atak, Şefika Dinçer, Duygu Deniz Usta, Aslı Emniyet Sert, Gülnur Take Kaplanoğlu, Yıldız Güney
{"title":"Synergistic Potential of GLP-1 Receptor Agonists and Radiotherapy in Breast Cancer Treatment: A New Therapeutic Avenue (TROD-GROG 006).","authors":"Ozum Atasoy, Elvan Anadol, Atiye Seda Yar Sağlam, Eyüb Yaşar Akdemir, Yasemin Şengün Coşkun, Ece Atak, Şefika Dinçer, Duygu Deniz Usta, Aslı Emniyet Sert, Gülnur Take Kaplanoğlu, Yıldız Güney","doi":"10.2174/0118744710381356250429045716","DOIUrl":"https://doi.org/10.2174/0118744710381356250429045716","url":null,"abstract":"<p><strong>Introduction: </strong>GLP-1 receptor agonists (GLP-1 RA) are drugs used to treat diabetes by enhancing insulin sensitivity and secretion. Recent studies suggest their potential anti-cancer effects, including anti-inflammatory and antioxidant properties. This study evaluates the combined effects of GLP-1 RAs and radiotherapy (RT) on breast cancer progression in a BALB/c mouse model.</p><p><strong>Materials and methods: </strong>In this study, BALB/c mice were injected with 4T1 breast cancer cells to induce tumors. The mice were randomly assigned to five groups: control, placebo, GLP-1 RA, RT, and combined GLP-1 RA with RT. Histological and immunohistochemical analyses were performed on the tumor tissues to assess changes in morphology and protein expression related to inflammation and apoptosis. In vitro, cell viability assays were also conducted on 4T1 cells to evaluate the effects of GLP-1 RA and RT.</p><p><strong>Results: </strong>The combination of GLP-1 RA and RT resulted in significant tumor size reduction compared to the other treatment groups. Histological analysis showed improved tissue morphology, with restored healthy appearance in tumors treated with both GLP-1 RA and radiotherapy. Immunohistochemical staining revealed changes in the expression of apoptosis-related proteins. In vitro assays demonstrated that the combined treatment significantly decreased the viability of 4T1 breast cancer cells.</p><p><strong>Conclusion: </strong>This study concludes that the GLP-1 RAs and RT combination enhances tumor control and improves histological outcomes in a breast cancer model. This approach offers a promising strategy for patients with coexisting diabetes and breast cancer, potentially improving treatment efficacy and patient outcomes.</p>","PeriodicalId":10991,"journal":{"name":"Current radiopharmaceuticals","volume":" ","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143955469","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Real-world Data on Intermediate-risk Differentiated Thyroid Cancer Biochemical Response to 3700 or 5550 MBq of [131I]Sodium Iodide. 3700或5550 MBq [131I]碘化钠对中度分化甲状腺癌生化反应的真实世界数据
IF 1.5 4区 医学
Current radiopharmaceuticals Pub Date : 2025-05-06 DOI: 10.2174/0118744710374569250415095218
Daniel M Machado, Daniel A Bulzico, Lídia F Fontes, Rossana C R de Mello, Simone Basso Locatelli, Priscilla B Pujatti
{"title":"Real-world Data on Intermediate-risk Differentiated Thyroid Cancer Biochemical Response to 3700 or 5550 MBq of [131I]Sodium Iodide.","authors":"Daniel M Machado, Daniel A Bulzico, Lídia F Fontes, Rossana C R de Mello, Simone Basso Locatelli, Priscilla B Pujatti","doi":"10.2174/0118744710374569250415095218","DOIUrl":"https://doi.org/10.2174/0118744710374569250415095218","url":null,"abstract":"<p><strong>Background: </strong>The ideal [131I]Sodium Iodide activity for intermediate-risk thyroid cancer treatment is still uncertaindue to the high heterogeneity of this disease in these patients.</p><p><strong>Objective: </strong>The objective of this study is to compare the biochemical responses to radioiodine therapy (RIT) of intermediate-risk thyroid cancer patients administered [131I]Sodium Iodide at 3700 MBq (100 mCi) and 5550 MBq (150 mCi) activities.</p><p><strong>Methods: </strong>A retrospective study was conducted by reviewing the medical records of intermediate- risk thyroid cancer patients who received RIT between 2016 and 2020 at a reference cancer hospital in Brazil. Sociodemographic and clinical data were evaluated at the time of diagnosis. Clinical data during two years of follow-up were reviewed, and biochemical responses were determined according to the American Thyroid Association (ATA, 2015 version). Responses to 3700 MBq (100 mCi) and 5550 MBq (150 mCi) of [131I]Sodium Iodide were compared.</p><p><strong>Results: </strong>No significant statistical differences were observed concerning the biochemical therapeutic responses of patients treated with 3700 MBq or 5550 MBq (p = 0.088). The presence of nodal metastasis and positive pre-RIT thyroglobulin did not influence biochemical responses to radioiodine.</p><p><strong>Conclusion: </strong>Intermediate risk thyroid-cancer patients presented similar therapeutic responses to 3700 MBq and 5550 MBq [131I]Sodium Iodide activities.</p>","PeriodicalId":10991,"journal":{"name":"Current radiopharmaceuticals","volume":" ","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143967992","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Nuclear Nanomedicines: Utilization of Radiolabelling Strategies, Drug Formulation, Delivery, and Regulatory Aspects for Disease Management. 核纳米医学:利用放射性标签策略、药物配方、递送和疾病管理的监管方面。
IF 1.5 4区 医学
Current radiopharmaceuticals Pub Date : 2025-04-29 DOI: 10.2174/0118744710373025250423042401
Neeraj Gupta, Kalpana Nagpal
{"title":"Nuclear Nanomedicines: Utilization of Radiolabelling Strategies, Drug Formulation, Delivery, and Regulatory Aspects for Disease Management.","authors":"Neeraj Gupta, Kalpana Nagpal","doi":"10.2174/0118744710373025250423042401","DOIUrl":"https://doi.org/10.2174/0118744710373025250423042401","url":null,"abstract":"<p><p>By integrating the sensitivity of nuclear medicine and the precision of nanotechnology, mankind can explore the very promising nuclear nanomedicine technology. Such integration enabled the imaging of biological processes at the molecular level which is a blessing to modern disease management. The present work is an effort to highlight the multifaceted applications of radiolabelled nanomaterials across various imaging modalities, formulation assessment, drug development, regulatory considerations, and therapeutic interventions. The present work highlights the application of radiolabelled nanomaterials for molecular imaging. The single-photon emission computed tomography (SPECT), positron emission tomography (PET); and hybrid multimodalities, along with their key features, are inherent parts of this discussion. The discussion continues with the assessment procedures of new formulations and their implications for drug delivery and the associated regulatory affairs. Cell tracking strategies that allow real-time monitoring of cellular behaviour in vivo; and radionuclide therapy with targeted and precise treatment are explained with the comparison of different strategies. This is followed by the explanation of how the drug delivery systems incorporating molecular imaging radiotracers enable tracking of in vivo drug behavior, further facilitating optimization of dosage forms and therapeutic efficacy. Thus, this manuscript provides a comprehensive overview of the utilization of radiolabelling strategies across the spectrum of drug formulation, delivery, and regulatory aspects, which is a way forward to future projections in nuclear nanomedicine. In conclusion, the emergence of nuclear nanomedicines is a disease management breakthrough in modern healthcare systems. This innovative approach not only provides tailored diagnostics but also offers innovative therapeutic solutions.</p>","PeriodicalId":10991,"journal":{"name":"Current radiopharmaceuticals","volume":" ","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143983256","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
RNA Binding Proteins are Pivotal Regulators of Cancer Radioresistance and Potential Targets for Preventing Tumor Recurrence. RNA结合蛋白是癌症放射耐药的关键调节因子和预防肿瘤复发的潜在靶点。
IF 1.5 4区 医学
Current radiopharmaceuticals Pub Date : 2025-04-29 DOI: 10.2174/0118744710366175250425101010
Vasanth Kanth Thasma LoganathBabu, Srisri Satishkartik, Vanshikaa Karthikeyan, Sayantani Chattopadhyay, Shriya P, Harin N Ganesh, Kirubakaran Rangasamy, Satish Ramalingam, ArulJothi Kandasamy Nagarajan
{"title":"RNA Binding Proteins are Pivotal Regulators of Cancer Radioresistance and Potential Targets for Preventing Tumor Recurrence.","authors":"Vasanth Kanth Thasma LoganathBabu, Srisri Satishkartik, Vanshikaa Karthikeyan, Sayantani Chattopadhyay, Shriya P, Harin N Ganesh, Kirubakaran Rangasamy, Satish Ramalingam, ArulJothi Kandasamy Nagarajan","doi":"10.2174/0118744710366175250425101010","DOIUrl":"https://doi.org/10.2174/0118744710366175250425101010","url":null,"abstract":"<p><p>RNA-binding proteins (RBPs) regulate gene expression at the post-transcriptional level and are important factors in cancer progression and response to various therapeutic strategies. Radioresistance, an obstacle caused due to various intrinsic and extrinsic factors, remains a major hindrance in the treatment of cancer and could lead to tumor recurrence. Though research is being conducted on the cause and association of radioresistance with various cellular and environmental factors, there remains much to be explored and discovered. The roles of several RNA-binding proteins in tumor progression and metastasis are well documented. In addition, recent studies suggest the connection between Cancer Stem Cells (CSCs) and chemoresistance. We and others have extensively studied the regulatory role of RBPs in regulating CSCs. Resistance to radiation therapy and the involvement of RBPs in this process is under-studied. In this review, we have provided an updated compilation of the significant role played by RBPs in radioresistance.</p>","PeriodicalId":10991,"journal":{"name":"Current radiopharmaceuticals","volume":" ","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143987151","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prediction of Recurrence using a Stacked Denoising Autoencoder and Multifaceted Feature Analysis of Pretreatment MRI in Patients with Nasopharyngeal Carcinoma. 应用叠置去噪自编码器预测鼻咽癌患者复发及预处理MRI多面特征分析。
IF 1.5 4区 医学
Current radiopharmaceuticals Pub Date : 2025-04-15 DOI: 10.2174/0118744710384129250327060846
Yibin Liu, Xianwen Wang, Jiongyi Li, Junxiao Gao, Bin He, Xianlong Wang, Lianfang Tian, Bin Li, Qianhui Qiu
{"title":"Prediction of Recurrence using a Stacked Denoising Autoencoder and Multifaceted Feature Analysis of Pretreatment MRI in Patients with Nasopharyngeal Carcinoma.","authors":"Yibin Liu, Xianwen Wang, Jiongyi Li, Junxiao Gao, Bin He, Xianlong Wang, Lianfang Tian, Bin Li, Qianhui Qiu","doi":"10.2174/0118744710384129250327060846","DOIUrl":"https://doi.org/10.2174/0118744710384129250327060846","url":null,"abstract":"<p><strong>Background: </strong>Strategies for predicting the recurrence of nasopharyngeal carcinoma need to be further development and validation. We developed a recurrence prediction model based on the fusion of multi-omics features from pre-treatment conventional magnetic resonance sequences (CE-T1W) in nasopharyngeal carcinoma (NPC) patients to predict posttreatment recurrence.</p><p><strong>Methods: </strong>We employed a deep unsupervised stacked denoising autoencoder (stacked denoising autoencoder, SDAE) and multi-omics feature fusion method to develop an NPC recurrence prediction model. Data and magnetic resonance images from 184 patients with newly diagnosed nasopharyngeal carcinoma (NPC), confirmed by pathological examination and who underwent radical comprehensive treatment, were collected. Propensity score matching (relapse: no recurrence = 1:1) was used to balance clinical factors that might influence recurrence, resulting in 136 matched cases. SDAE was utilized to extract deep features, combined with the fusion features of radiomics (Radiomics) features and clinical features, using support vector machine (SVM), multilayer perceptron (MLP), logistic regression (LR) and random forest (RF) machine learning methods to build models. The mean area under the curve (AUC), accuracy, sensitivity, and specificity of each model were compared to evaluate their performance in predicting recurrence.</p><p><strong>Results: </strong>After parameter adjustment, 12 machine learning models based on different fusion features were developed. Model 1 (Radiomics+AutoEncoder+Clinical+SVM) achieved better prediction performance, with a mean AUC, accuracy, sensitivity, and specificity of 0.89 (95% CI: 0.84- 0.93), 81.5%, 67.3% and 97.9%, respectively. Model 2 (Radiomics+ AutoEncoder+SVM), Model 3 (Radiomics+SVM), Model 4 (Radiomics+ AutoEncoder+Clinical+MLP), Model 5 (Radiomics+Auto Encoder+MLP), Model 6 (Radiomics+MLP), Model 7 (Radiomics+AutoEncoder+Clinical+LR), Model 8 (Radiomics+AutoEncoder+LR), Model 9 (Radiomics+LR), Model 10 (Radiomics+Auto Encoder+Clinical+RF), Model 11 (Radiomics+AutoEncoder+RF), Model 12 (Radiomics+RF) achieved AUCs of 0.87, 0.87, 0.82, 0.80, 0.82, 0.82, 0.78, 0.80, 0.81, 0.80, and 0.82, respectively.</p><p><strong>Conclusion: </strong>The SVM model for predicting the recurrence of nasopharyngeal carcinoma based on radiomics+autoEncoder+clinical fusion features established by CE-T1WI of nasopharyngeal carcinoma patients before treatment, achieved good predictive performance and is relatively reliable, which can provide more information and help for clinical diagnosis and treatment decisions and interventions.</p>","PeriodicalId":10991,"journal":{"name":"Current radiopharmaceuticals","volume":" ","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143969177","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Central Composite Design and Artificial Neural Network Coupled with Genetic Algorithm in Optimization and Modeling of the Radiolabeling Process of 177Lu-hydroxyapatite as a Potential Radiosynovectomy Agent. 中心复合设计与人工神经网络结合遗传算法对177lu -羟基磷灰石作为潜在放射滑膜切除药物的放射标记过程进行优化建模。
IF 1.5 4区 医学
Current radiopharmaceuticals Pub Date : 2025-03-03 DOI: 10.2174/0118744710336283250227020659
Sima Attar Nosrati, Maryam Salahinejad, Mohammad Reza Aboudzadeh, Mojtaba Amiri, Ali Roozbahani
{"title":"The Central Composite Design and Artificial Neural Network Coupled with Genetic Algorithm in Optimization and Modeling of the Radiolabeling Process of 177Lu-hydroxyapatite as a Potential Radiosynovectomy Agent.","authors":"Sima Attar Nosrati, Maryam Salahinejad, Mohammad Reza Aboudzadeh, Mojtaba Amiri, Ali Roozbahani","doi":"10.2174/0118744710336283250227020659","DOIUrl":"https://doi.org/10.2174/0118744710336283250227020659","url":null,"abstract":"<p><strong>Background: </strong>A promising material used in radiation synovectomy of small joints is hydroxyapatite, labeled with 177Lu. During the design and production of radiopharmaceuticals, the condition of the radiolabeling process directly influences the radiochemical yield and consequently the quality of the final product so this process necessitates precise optimization.</p><p><strong>Methods: </strong>In this investigation, a central composite design based on response surface methodology and artificial neural networks modeling coupled with genetic algorithm technique is applied to build predictive models and explore key parameters' effect in hydroxyapatite's radiolabeling process with 177Lu radionuclide. The variables that directly affected the labeling reaction were the initial 177Lu radioactivity, pH, radiolabeling reaction time, and temperature.</p><p><strong>Results: </strong>Based on the validation data set, the statistical values demonstrate that the artificial neural networks model performs better than the response surface methodology model. The artificial neural networks model has a small mean squared error (9.08 artificial neural networks < 12.36 response surface methodology) and a high coefficient of determination (R2: 0.99 artificial neural networks > 0.93 response surface methodology). The optimum conditions to achieve maximum radiochemical yield based on response surface methodology using artificial neural networks modeling coupled with genetic algorithm were at the initial radioactivity of 177Lu radionuclide = 0.082 Gigabecquerel (GBq), pH = 6.75, time= 22 (min), and temperature = 37.8 (oC) Conclusion: The ability to generate more data with fewer experiments for optimization and improved production is a pertinent advantage of multivariate optimization methods over traditional methods in radiation-related activities. The central composite design and artificial neural network- genetic algorithm optimization approaches are successfully utilized to create prediction models and investigate the impact of critical variables in the radiolabeling of hydroxyapatite with 177Lu radionuclide.</p>","PeriodicalId":10991,"journal":{"name":"Current radiopharmaceuticals","volume":" ","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143540500","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A New Approach to Synthesizing Carbon-11-PBR28 and its Clinical Validation in ALS Patients. 合成碳-11- pbr28的新方法及其在ALS患者中的临床验证
IF 1.5 4区 医学
Current radiopharmaceuticals Pub Date : 2025-02-26 DOI: 10.2174/0118744710341203250220042349
Pardeep Kumar, Aishwarya Kumar, Muddasu Keerthipriya, Chandrika H, Atchayaram Nalini, Seena Vengalil, Kirti Sitani, Chandana Nagaraj, Saikat Dey, Monojit Debnath, Vijayalakshmi K, Talakad N Satyaprabha
{"title":"A New Approach to Synthesizing Carbon-11-PBR28 and its Clinical Validation in ALS Patients.","authors":"Pardeep Kumar, Aishwarya Kumar, Muddasu Keerthipriya, Chandrika H, Atchayaram Nalini, Seena Vengalil, Kirti Sitani, Chandana Nagaraj, Saikat Dey, Monojit Debnath, Vijayalakshmi K, Talakad N Satyaprabha","doi":"10.2174/0118744710341203250220042349","DOIUrl":"https://doi.org/10.2174/0118744710341203250220042349","url":null,"abstract":"<p><strong>Background: </strong>Many studies have reported Translocator Protein (TSPO) overexpression in many neurological disorders. Carbon-11[11C]PBR28 is a widely used TSPO Positron Emission Tomography (PET) radiopharmaceutical. We have compared HPLC-based purification with cartridge-based purification and performed PET-MR imaging in ALS patients.</p><p><strong>Methods: </strong>[11C]PBR28 has been synthesized using an HPLC-based and cartridge-based purification technique in the FX2C chemistry module. All necessary quality controls were performed and compared. We injected 350 ± 20 MBq of the [11C]PBR28 intravenously into human patients (n = 6) diagnosed with amyotrophic lateral syndrome (ALS) and performed simultaneous PETMR dynamic imaging.</p><p><strong>Results: </strong>The radiochemical purity was greater than 95% with both methods. The radiochemical yield was 11.8 ± 3.3%, and molar activity was 253 ± 20.9 GBq/μmol with a total synthesis time of 25 ± 2 min in the HPLC-based purification method. Whereas the radiochemical yield was 53.0 ± 3.6%, and molar activity was 885 ± 17.7 GBq/μmol with a total synthesis time of 12 ± 2 min in the cartridge-based purification method. We have compared PET-MR imaging of ALS limb onset (n =3) with ALS bulbar and limb onset (n =3), and there was a difference in time activity curves. The activity was higher in the precentral gyrus and cerebellum at 2.5 ± 0.5 min in bulbar cases with an SUV of 2.3 ± 0.3, whereas ALS limb onset showed the highest uptake at 0.5 ± 0.2 min with an SUV of 1.5 ± 0.2.</p><p><strong>Conclusion: </strong>The cartridge-based method provided higher radiochemical yield and molar activity.</p>","PeriodicalId":10991,"journal":{"name":"Current radiopharmaceuticals","volume":" ","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143515002","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Dilemma on Pancreatic Uncinate Process Uptake on Ga68-DOTA Peptide PET/CT in Pediatric Neuroblastoma: Physiologic or Metastases? 儿童神经母细胞瘤的Ga68-DOTATE PET/CT对胰腺棘突摄取的困境:生理性还是转移性?
IF 1.5 4区 医学
Current radiopharmaceuticals Pub Date : 2025-02-17 DOI: 10.2174/0118744710226018250206105536
Nedim C M Gülaldi, Nadide Basak Gülleroglu, Selma Cakmakci, Fatma Arzu Görtan, Neriman Sari
{"title":"Dilemma on Pancreatic Uncinate Process Uptake on Ga68-DOTA Peptide PET/CT in Pediatric Neuroblastoma: Physiologic or Metastases?","authors":"Nedim C M Gülaldi, Nadide Basak Gülleroglu, Selma Cakmakci, Fatma Arzu Görtan, Neriman Sari","doi":"10.2174/0118744710226018250206105536","DOIUrl":"10.2174/0118744710226018250206105536","url":null,"abstract":"<p><strong>Objective: </strong>The Ga68-DOTATATE PET/CT scan is an alternative imaging modality for the follow-up of children with neuroblastoma when the I123-MIBG scan was negative or weak. Somatostatin receptors (SSR) can be expressed in neuroblastoma lesions, and when this happens, targeting these receptors may be a good alternative to treating this disease in addition to conventional treatments. Our aim is to focus on the interpretation of one of the physiological tracer uptake sites, the uncinate process of the pancreas, using DW-MRI scans.</p><p><strong>Methods: </strong>We present and discuss 4 cases with neuroblastoma for a technical note. Imaging scans for SSR were performed using Ga68-DOTATATE PET/CT, and all showed varying degrees of increased uptake at the uncinate process of the pancreas on PET/CT images. We also performed a DW-MRI study to distinguish physiologic uptake in this region of the pancreas from metastatic involvement.</p><p><strong>Results: </strong>Two of them showed diffusion restriction, with one of them also showing multiple masses within the liver. The other 2 children with high pancreatic uncinate process uptake did not exhibit any findings that indicated pancreatic involvement in the disease, based on DW-MRI images and clinical findings.</p><p><strong>Conclusion: </strong>We recommend comparing DW-MRI scans and SSR-PET/CT scans to determine the true state of physiologically elevated SSR concentration and consequently indicate increased uptake on the images. The radiotracer concentration at the high uptake site did not appear to correlate with malignant involvement of the organ. The higher number of patients may allow a statistical comparison of the tracer with malignancy status.</p>","PeriodicalId":10991,"journal":{"name":"Current radiopharmaceuticals","volume":" ","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-02-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143448511","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信